Lena M. Unterrainer
Ismaninger Str. 22
Munich, BY 81675, Germany
Munich, BY 81675, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications
Metformin and renal dosimetry in patients undergoing [177Lu]Lu-PSMA therapy: reduced kidney absorbed dose without impact on tumor dosimetry.
Journal: European journal of nuclear medicine and molecular imaging
Published: April 29, 2026
Baseline 18F-FDG PET/CT metabolic parameters and systemic inflammatory markers in advanced NSCLC treated with first-line immunotherapy: an exploratory retrospective analysis.
Journal: Frontiers in oncology
Published: March 23, 2026
Impact of different PSMA PET-based eligibility criteria on outcome of [177Lu]Lu-PSMA radioligand therapy using [18F]rhPSMA-7/[18F]rhPSMA-7.3 (Flotufolastat).
Journal: EJNMMI research
Published: January 12, 2026
A Whole-Body PSMA-PET/CT dataset with manually annotated tumor lesions.
Journal: Scientific data
Published: December 10, 2025
Investigation of iterative deconvolution in 177Lu-SPECT imaging for lesion dosimetry.
Journal: EJNMMI physics
Published: November 26, 2025
Estimation of split renal function on PET using the SSTR-targeting radioligands [18F]SiTATE, [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTA-TOC in a theranostic setting.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 26, 2025
Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 17, 2025
Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study.
Journal: Urologia internationalis
Published: November 11, 2025
The role of non-FDG agents in PET imaging of bladder cancer.
Journal: Seminars in nuclear medicine
Published: November 05, 2025
Prognostic Value of PSMA PET-Derived Tumor Burden Stratification in Metastatic Hormone-Sensitive Prostate Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 04, 2025
Options in nuclear medicine for advanced prostate cancer in practice
Journal: Radiologie (Heidelberg, Germany)
Published: October 20, 2025
Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 13, 2025
Last Updated: 09/26/2026